← Back to patent-cliff list
CAS 106-40-1
4-Bromophenylaminep-Bromoaniline4-bromoaniline
Codes: Imipenem-017, (XXVIII)700647-1-c, ZOLM-017
Application context (from source-drug indications)
Bacterial pneumoniaCilastatin Sodium/Imipenem/RelebactamHospital-acquired pneumoniaCilastatin Sodium/Imipenem/RelebactamInfectious diseaseCilastatin Sodium/Imipenem/RelebactamBacteraemiaCilastatin Sodium/Imipenem/RelebactamVentilator-associated pneumoniaCilastatin Sodium/Imipenem/RelebactamHealthcare-associated pneumoniaCilastatin Sodium/Imipenem/RelebactamBacterial infectionImipenemGonorrhoeaImipenemBacillus anthracis infectionImipenem蠕形螨性睑缘炎Lotilaner螨虫感染Lotilaner莱姆病LotilanerRosaceaLotilaner睑板腺功能障碍LotilanerMigraineZolmitriptan
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Cilastatin Sodium/Imipenem/Relebactam | Tier C — Watch / trade | - |
| Imipenem | Tier C — Watch / trade | - |
| Lotilaner | Tier C — Watch / trade | - |
| Zolmitriptan | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-Methoxyphenylamine→1-Amino-4-fluorobenzene→4-Bromophenylamine→4-Ethoxyphenylamine→omega-Bromoacetophenone→Chloroacetyl chloride→2-Iodo-1-(3-methoxyphenyl)ethanone→1-Bromo-3,3-dimethylbutan-2-one<-fgf->→2-[(4-Methoxyphenyl)amino]-1-phenylethanone→1-[(4-Methoxyphenyl)amino]acetone→1-[(4-Fluorophenyl)amino]acetone→2-[(4-Bromophenyl)amino]-1-(3-methoxyphenyl)ethanone→1-[(4-Ethoxyphenyl)amino]-3,3-dimethylbutan-2-one→(3S)-4-Benzoyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-(2,2-dimethylpropanoyl)-1-(4-ethoxyphenyl)azetidin-2-one→(2R,3R)-3-Methyloxirane-2-carboxylic acid→L-Threonine→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxo-2-phenylethyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Fluorophenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Bromophenyl)-N-[2-(3-methoxyphenyl)-2-oxoethyl]-3-methyloxirane-2-carboxamide→(2R,3R)-N-(3,3-Dimethyl-2-oxobutyl)-N-(4-ethoxyphenyl)-3-methyloxirane-2-carboxamide→(3S)-4-Benzoyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-1-(4-fluorophenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-hydroxyethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-4-(2,2-Dimethylpropanoyl)-1-(4-ethoxyphenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(1E)-1-[(4-Methoxyphenyl)imino]acetone→S-Pyridin-2-yl (3R)-3-[[tert-butyl(dimethyl)silyl]oxy]butanethioate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-ethoxyphenyl)-4-oxoazetidin-2-yl acetate→(2S,3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate
4-Methoxyphenylamine→1-Amino-4-fluorobenzene→4-Bromophenylamine→4-Ethoxyphenylamine→omega-Bromoacetophenone→Chloroacetyl chloride→2-Iodo-1-(3-methoxyphenyl)ethanone→1-Bromo-3,3-dimethylbutan-2-one<-fgf->→2-[(4-Methoxyphenyl)amino]-1-phenylethanone→1-[(4-Methoxyphenyl)amino]acetone→1-[(4-Fluorophenyl)amino]acetone→2-[(4-Bromophenyl)amino]-1-(3-methoxyphenyl)ethanone→1-[(4-Ethoxyphenyl)amino]-3,3-dimethylbutan-2-one→(3S)-4-Benzoyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-(2,2-dimethylpropanoyl)-1-(4-ethoxyphenyl)azetidin-2-one→(2R,3R)-3-Methyloxirane-2-carboxylic acid→L-Threonine→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxo-2-phenylethyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Fluorophenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Bromophenyl)-N-[2-(3-methoxyphenyl)-2-oxoethyl]-3-methyloxirane-2-carboxamide→(2R,3R)-N-(3,3-Dimethyl-2-oxobutyl)-N-(4-ethoxyphenyl)-3-methyloxirane-2-carboxamide→(3S)-4-Benzoyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-1-(4-fluorophenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-hydroxyethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-4-(2,2-Dimethylpropanoyl)-1-(4-ethoxyphenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(1E)-1-[(4-Methoxyphenyl)imino]acetone→S-Pyridin-2-yl (3R)-3-[[tert-butyl(dimethyl)silyl]oxy]butanethioate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-ethoxyphenyl)-4-oxoazetidin-2-yl acetate→(2S,3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate
4,4-diethoxy-N,N-dimethylbutan-1-amine→4-bromoaniline→(4-bromophenyl)hydrazine→2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethan-1-amine→methyl 2-acetamidoacrylate→methyl (Z)-2-acetamido-3-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)acrylate→methyl (S)-2-acetamido-3-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)propanoate→(S)-N-(1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-3-hydroxypropan-2-yl)acetamide→(S)-2-amino-3-(3-(2-aminoethyl)-1H-indol-5-yl)propan-1-ol hydrochloride
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 2-bromo-3-methyl-5-acetylthiophene Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | methyl 5-acetyl-3-methylthiophene-2-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 5-acetyl-3-methyl-2-Thiophenecarboxylic acid Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.